Pulmonary Fibrosis Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033
Persistence Market Research는 최근 폐 섬유증 치료 세계 시장에 대한 종합적인 보고서를 발표했습니다. 이 보고서는 시장 성장 촉진요인, 동향, 기회, 과제 등 주요 시장 역학을 상세하게 분석하여 시장 상황에 대한 귀중한 통찰력을 제공합니다. 이 조사 보고서는 2024년부터 2033년까지 폐 섬유증 치료 시장의 성장 궤도를 예측하는 독점 데이터와 통계를 제공합니다.
주요 인사이트
- 시장 규모(2024E) : 31억 달러
- 시장 예측치(2033F) : 56억 달러
- 세계 시장 성장률(CAGR 2024-2033년) : 6.8%
폐 섬유증 치료 시장 - 보고 범위:
폐 섬유증 치료는 섬유화 폐 질환의 진행을 관리하고 역전시킬 가능성을 목적으로 하는 다양한 치료 접근법을 다룹니다. 이러한 치료에는 약리학적 개입, 산소 요법, 폐 재활, 심한 경우 폐 이식 등이 포함됩니다. 이 시장은 병원, 전문 클리닉, 폐 재활센터, 재택치료 현장에서 항섬유화약, 면역억제제, 신규 생물제제 등 다양한 치료 옵션을 제공합니다.
시장 성장 촉진요인:
세계 폐 섬유증 치료 시장은 특발성 폐 섬유증(IPF) 및 유육종증과 같은 호흡기 질환의 유병률 증가와 같은 여러 요인들에 의해 견인되고 있습니다. 고령화 인구 증가와 이에 따른 만성 질환의 이환율 증가는 시장 확대에 크게 기여하고 있습니다. 약물 개발의 진전, 특히 피르페니돈 및 닌테다닙과 같은 항섬유화 요법의 출현은 환자의 예후를 개선하는 효과적인 치료 옵션을 제공함으로써 시장 성장을 뒷받침하고 있습니다. 게다가, 의료 종사자와 환자들 사이에서 조기 진단과 치료 개시에 대한 의식이 높아지고 있는 것도 시장 수요를 뒷받침하고 있습니다.
시장 성장 억제요인:
유망한 성장이 예상되는 것, 폐 섬유증 치료 시장은 높은 치료비, 제한된 치료법만이 있다는 것, 의약품 승인을 위한 엄격한 규제 요건 등과 관련된 과제에 직면하고 있습니다. 일부 지역에는 경제적 제약이 있으며 건강 관리 인프라가 불충분하기 때문에 특히 신흥 국가에서는 시장 침투를 방해합니다. 게다가, 폐 섬유증의 진단과 관리는 복잡하기 때문에 전문적인 건강 관리에 대한 지식이 필요하며 효과적인 치료에 대한 추가 장벽이되었습니다.
시장 기회:
폐 섬유증 치료 시장은 새로운 치료 대상과 개인화된 의료 접근법에 중점을 둔 연구 개발이 진행 중이기 때문에 비즈니스 기회가 풍부합니다. 이미징 및 바이오마커 식별에서의 혁신은 질병의 탐지와 모니터링을 강화하고 조기 개입과 개인화 치료 계획을 촉진합니다. 제약 기업과 학술 연구 기관의 전략적 제휴는 혁신을 촉진하고 획기적인 치료법의 도입을 가속화합니다. 또한, 원격 의료와 디지털 건강 솔루션의 통합은 환자의 전문 치료에 대한 액세스를 확대하고 치료의 모호성을 향상시켜 시장 성장을 자극합니다.
이 보고서에서 다루는 주요 질문
- 폐 섬유증 치료 시장의 세계 성장을 가속하는 주요 요인은 무엇인가?
- 다양한 건강 관리 환경에서 어떤 치료 양식과 치료 클래스가 채용을 촉진하고 있는가?
- 기술의 진보는 폐 섬유증 치료 시장 경쟁 구도를 어떻게 바꾸고 있는가?
- 폐 섬유증 치료 시장에 기여하는 주요 기업은 누구이며 시장 관련성을 유지하기 위해 어떤 전략을 채택하고 있는가?
- 세계의 폐 섬유증 치료 시장에서의 새로운 동향과 미래 전망은?
목차
제1장 주요 요약
제2장 시장 개요
- 시장 범위/ 분류
- 시장의 정의/ 범위/ 제한
- 포함과 제외
제3장 주요 시장 동향
- 시장에 영향을 주는 주요 동향
- 혁신/개발 동향
제4장 중요 성공 요인
- 파이프라인 평가
- 질병 역학
- 시장 기업의 주요 프로모션 전략
- 지역별 채용/적응 분석
- 규제 시나리오
- PESTEL 분석
- Porter's Five Forces 분석
제5장 시장 배경
- 거시경제 요인
- 예측 요인- 관련성과 영향
- 시장 역학
제6장 COVID-19 위기 분석
- COVID-19와 영향 분석
- 치료 유형별 수익
- 적응증별 수익
- 유통채널별 수익
- 지역별 수익
- 2024년 시장 시나리오
제7장 세계의 폐 섬유증 치료 시장 수요(가치 또는 규모) 분석
- 2019-2023년 시장 매출의 역사적 분석
- 현재 및 미래 시장 매출 예측(2024-2033년)
- 전년대비 성장 동향 분석
- 절대적인 $ 기회 분석
제8장 세계의 폐 섬유증 치료 시장 분석(치료 유형별)
- 소개/ 주요 조사 결과
- 2019-2023년의 치료 유형별 시장 규모의 역사적 분석
- 현재 및 미래 시장 규모의 분석과 예측, 치료 유형별(2024-2033년)
- 단독요법
- 피르페니돈 요법
- 닌테다닙 요법
- 코르티코스테로이드 요법
- 병용 요법
- 피르페니돈과 코르티코스테로이드
- 닌테다닙과 코르티코스테로이드
- 피르페니돈과 진해제
- 기타
- 치료
- 치료 유형별 시장의 매력 분석
제9장 세계의 폐 섬유증 치료제 시장 분석(적응증별)
- 소개/ 주요 조사 결과
- 과거 시장 규모 분석, 적응증별(2019-2023년)
- 현재 및 미래 시장 규모의 분석과 예측, 적응증별(2024-2033년)
- 적응증별 시장의 매력 분석
제10장 세계의 폐 섬유증 치료 시장 분석(유통 채널별)
- 소개/ 주요 조사 결과
- 과거 시장 규모 분석, 유통 채널별(2019-2023년)
- 현재 및 미래 시장 규모의 분석과 예측, 유통 채널별(2024-2033년)
- 유통 채널별 시장의 매력 분석
제11장 지역별 폐 섬유증 치료 시장 분석
- 소개
- 지역별 시장 규모의 과거 분석(2019-2023년)
- 현재 및 미래 시장 규모의 지역별 분석과 예측(2024-2033년)
- 북미
- 라틴아메리카
- 유럽
- 동아시아
- 남아시아
- 오세아니아
- 중동 및 아프리카(중동 및 아프리카)
- 지역별 시장의 매력 분석
제12장 북미의 폐 섬유증 치료 시장 분석
제13장 라틴아메리카의 폐 섬유증 치료 시장 분석
제14장 유럽의 폐 섬유증 치료 시장 분석
제15장 동아시아의 폐 섬유증 치료 시장 분석
제16장 남아시아의 폐섬유증 치료 시장 분석
제17장 오세아니아의 폐 섬유증 치료 시장
제18장 중동 및 아프리카(중동 및 아프리카)의 폐 섬유증 치료 시장 분석
제19장 시장 구조 분석
- 기업 Tier별 시장 분석
- 주요 기업의 시장 점유율 분석
- 시장현재분석
제20장 경쟁 분석
- 경쟁 대시보드
- 경쟁의 상세
- F. Hoffman-La Roche Ltd.
- Boehringer Ingelheim
- International GmbH
- Cipla Ltd(Cipla)
- Gilead Sciences, Inc.
- Bristol-Myers Squibb Company
- FibroGen Inc.,
- Galecto, Inc.
제21장 사용된 전제조건과 약어
제22장 조사 방법
JHS
Persistence Market Research has recently released a comprehensive report on the global market for pulmonary fibrosis treatment. The report provides a detailed analysis of key market dynamics, including drivers, trends, opportunities, and challenges, offering valuable insights into the market landscape. This research publication offers exclusive data and statistics projecting the growth trajectory of the pulmonary fibrosis treatment market from 2024 to 2033.
Key Insights:
- Market Size (2024E): USD 3.1 Billion
- Projected Market Value (2033F): USD 5.6 Billion
- Global Market Growth Rate (CAGR 2024 to 2033): 6.8%
Pulmonary Fibrosis Treatment Market - Report Scope:
Pulmonary fibrosis treatment addresses a range of therapeutic approaches aimed at managing and potentially reversing the progression of fibrotic lung diseases. These treatments include pharmacological interventions, oxygen therapy, pulmonary rehabilitation, and in severe cases, lung transplantation. The market serves hospitals, specialty clinics, pulmonary rehabilitation centers, and homecare settings, offering a variety of treatment options such as antifibrotic drugs, immunosuppressants, and novel biologics.
Market Growth Drivers:
The global pulmonary fibrosis treatment market is driven by several factors, including increasing prevalence of respiratory disorders such as idiopathic pulmonary fibrosis (IPF) and sarcoidosis. Growing aging population and associated higher incidence of chronic diseases contribute significantly to market expansion. Advances in drug development, particularly the emergence of antifibrotic therapies like pirfenidone and nintedanib, bolster market growth by providing effective treatment options with improved patient outcomes. Additionally, rising awareness about early diagnosis and treatment initiation among healthcare providers and patients propels market demand.
Market Restraints:
Despite promising growth prospects, the pulmonary fibrosis treatment market faces challenges related to high treatment costs, limited availability of curative treatments, and stringent regulatory requirements for drug approval. Economic constraints in some regions, coupled with insufficient healthcare infrastructure, hinder market penetration, especially in developing countries. Furthermore, the complexity of diagnosing and managing pulmonary fibrosis necessitates specialized healthcare expertise, posing additional barriers to effective treatment.
Market Opportunities:
The pulmonary fibrosis treatment market presents opportunities driven by ongoing research and development initiatives focused on novel therapeutic targets and personalized medicine approaches. Technological innovations in diagnostic imaging and biomarker identification enhance disease detection and monitoring, facilitating early intervention and personalized treatment plans. Strategic collaborations between pharmaceutical companies and academic research institutions foster innovation and accelerate the introduction of breakthrough therapies. Moreover, the integration of telemedicine and digital health solutions expands patient access to specialized care and improves treatment adherence, thereby stimulating market growth.
Key Questions Answered in the Report:
- What are the primary factors driving the growth of the pulmonary fibrosis treatment market globally?
- Which treatment modalities and therapeutic classes are driving adoption across different healthcare settings?
- How are technological advancements reshaping the competitive landscape of the pulmonary fibrosis treatment market?
- Who are the key players contributing to the pulmonary fibrosis treatment market, and what strategies are they employing to maintain market relevance?
- What are the emerging trends and future prospects in the global pulmonary fibrosis treatment market?
Competitive Intelligence and Business Strategy:
Leading players in the global pulmonary fibrosis treatment market, including major pharmaceutical companies and biotechnology firms, focus on expanding their product portfolios through strategic acquisitions, partnerships, and licensing agreements. Companies invest heavily in clinical trials to demonstrate efficacy and safety profiles of new treatments, ensuring regulatory approval and market acceptance. Furthermore, patient education initiatives and advocacy efforts by healthcare organizations raise awareness about pulmonary fibrosis, driving early diagnosis and treatment initiation.
Key Companies Profiled:
- F. Hoffman - La Roche Ltd.
- Boehringer Ingelheim
- International GmbH
- Cipla Ltd (Cipla)
- Gilead Sciences, Inc.
- Bristol-Myers Squibb Company
- FibroGen Inc.,
- Galecto, Inc.
Key Segments Covered in Pulmonary Fibrosis Treatment Industry Research
By Therapy Type:
- Monotherapy
- Combination Therapy
- Symptomatic Treatment
By Indication:
- Idiopathic Pulmonary Fibrosis (IPF)
- Familial PF
- Others
By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Mail Order Pharmacy
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Table of Contents
1. Executive Summary
- 1.1. Global Market Outlook
- 1.2. Demand Side Trends
- 1.3. Supply Side Trends
- 1.4. Analysis and Recommendations
2. Market Overview
- 2.1. Market Coverage / Taxonomy
- 2.2. Market Definition / Scope / Limitations
- 2.3. Inclusions and Exclusions
3. Key Market Trends
- 3.1. Key Trends Impacting the Market
- 3.2. Innovation / Development Trends
4. Key Success Factors
- 4.1. Pipeline Assessment
- 4.2. Disease Epidemiology
- 4.3. Key Promotional Strategies by Market Players
- 4.4. Adoption/ Indication Analysis by region
- 4.5. Regulatory Scenario
- 4.6. PESTEL Analysis
- 4.7. Porter's Analysis
5. Market Background
- 5.1. Macro-Economic Factors
- 5.1.1. Global GDP Growth Outlook
- 5.1.2. Global Healthcare Expenditure Outlook
- 5.1.3. Growth of Pharmaceutical Sector in Emerging nations
- 5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Top Companies Historical Growth
- 5.2.2. Growing Demand for Pulmonary Fibrosis Treatment
- 5.2.3. Pipeline assessments
- 5.2.4. Increasing Investment in Pharmaceutical
- 5.2.5. Costs of Pulmonary Fibrosis Treatment
- 5.2.6. Adoption of Pulmonary Fibrosis Treatment
- 5.2.7. Rise in Sales of Medical Devices
- 5.2.8. Regulatory Framework
- 5.2.9. Rising Disease Epidemic
- 5.2.10. Launch of New Drug
- 5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
- 6.1. COVID-19 and Impact Analysis
- 6.1.1. Revenue By Therapy Type
- 6.1.2. Revenue By Indication
- 6.1.3. Revenue By Distribution Channel
- 6.1.4. Revenue By Region
- 6.2. 2024 Market Scenario
7. Global Pulmonary Fibrosis Treatment Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033
- 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
- 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis
8. Global Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Therapy Type
- 8.1. Introduction / Key Findings
- 8.2. Historical Market Size (US$ Bn) Analysis By Therapy Type, 2019-2023
- 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Therapy Type, 2024-2033
- 8.3.1. Monotherapy
- 8.3.1.1. Pirfenidone Therapy
- 8.3.1.2. Nintedanib Therapy
- 8.3.1.3. Corticosteroids Therapy
- 8.3.2. Combination Therapy
- 8.3.2.1. Pirfenidone & Corticosteroid
- 8.3.2.2. Nintedanib & Corticosteroid
- 8.3.2.3. Pirfenidone & Antitussive
- 8.3.2.4. Others
- 8.3.3. Symptomatic Treatment
- 8.4. Market Attractiveness Analysis By Therapy Type
9. Global Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Indication
- 9.1. Introduction / Key Findings
- 9.2. Historical Market Size (US$ Bn) Analysis, By Indication, 2019-2023
- 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Indication, 2024-2033
- 9.3.1. Idiopathic Pulmonary Fibrosis (IPF)
- 9.3.2. Familial PF
- 9.3.3. Others
- 9.4. Market Attractiveness Analysis By Indication
10. Global Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channel
- 10.1. Introduction / Key Findings
- 10.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2023
- 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2024-2033
- 10.3.1. Hospital Pharmacy
- 10.3.2. Retail Pharmacy
- 10.3.3. Mail Order Pharmacy
- 10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033, by Region
- 11.1. Introduction
- 11.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
- 11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Region, 2024-2033
- 11.3.1. North America
- 11.3.2. Latin America
- 11.3.3. Europe
- 11.3.4. East Asia
- 11.3.5. South Asia
- 11.3.6. Oceania
- 11.3.7. Middle East and Africa (MEA)
- 11.4. Market Attractiveness Analysis By Region
12. North America Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033
- 12.1. Introduction
- 12.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
- 12.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
- 12.3.1. By Country
- 12.3.1.1. U.S.
- 12.3.1.2. Canada
- 12.3.2. By Therapy Type
- 12.3.3. By Indication
- 12.3.4. By Distribution Channel
- 12.4. Market Attractiveness Analysis
- 12.4.1. By Country
- 12.4.2. By Therapy Type
- 12.4.3. By Indication
- 12.4.4. By Distribution Channel
- 12.5. Market Trends
- 12.6. Key Market Participants - Intensity Mapping
- 12.7. Drivers and Restraints - Impact Analysis
- 12.8. Country Level Analysis & Forecast
- 12.8.1. U.S. Pulmonary Fibrosis Treatment Market Analysis
- 12.8.1.1. .Introduction
- 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 12.8.1.2.1. By Therapy Type
- 12.8.1.2.2. By Indication
- 12.8.1.2.3. By Distribution Channel
- 12.8.2. Canada Pulmonary Fibrosis Treatment Market Analysis
- 12.8.2.1. Introduction
- 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 12.8.2.2.1. By Therapy Type
- 12.8.2.2.2. By Indication
- 12.8.2.2.3. By Distribution Channel
13. Latin America Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033
- 13.1. Introduction
- 13.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
- 13.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
- 13.3.1. By Country
- 13.3.1.1. Mexico
- 13.3.1.2. Brazil
- 13.3.1.3. Argentina
- 13.3.1.4. Rest of Latin America
- 13.3.2. By Therapy Type
- 13.3.3. By Indication
- 13.3.4. By Distribution Channel
- 13.4. Market Attractiveness Analysis
- 13.4.1. By Country
- 13.4.2. By Therapy Type
- 13.4.3. By Indication
- 13.4.4. By Distribution Channel
- 13.5. Market Trends
- 13.6. Key Market Participants - Intensity Mapping
- 13.7. Drivers and Restraints - Impact Analysis
- 13.8. Country Level Analysis & Forecast
- 13.8.1. Mexico Pulmonary Fibrosis Treatment Market Analysis
- 13.8.1.1. Introduction
- 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 13.8.1.2.1. By Therapy Type
- 13.8.1.2.2. By Indication
- 13.8.1.2.3. By Distribution Channel
- 13.8.2. Brazil Pulmonary Fibrosis Treatment Market Analysis
- 13.8.2.1. Introduction
- 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 13.8.2.2.1. By Therapy Type
- 13.8.2.2.2. By Indication
- 13.8.2.2.3. By Distribution Channel
- 13.8.3. Argentina Pulmonary Fibrosis Treatment Market Analysis
- 13.8.3.1. Introduction
- 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 13.8.3.2.1. By Therapy Type
- 13.8.3.2.2. By Indication
- 13.8.3.2.3. By Distribution Channel
14. Europe Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033
- 14.1. Introduction
- 14.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
- 14.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
- 14.3.1. By Country
- 14.3.1.1. Germany
- 14.3.1.2. Italy
- 14.3.1.3. France
- 14.3.1.4. U.K.
- 14.3.1.5. Spain
- 14.3.1.6. Russia
- 14.3.1.7. BENELUX
- 14.3.1.8. Rest of Europe
- 14.3.2. By Therapy Type
- 14.3.3. By Indication
- 14.3.4. By Distribution Channel
- 14.4. Market Attractiveness Analysis
- 14.4.1. By Country
- 14.4.2. By Therapy Type
- 14.4.3. By Indication
- 14.4.4. By Distribution Channel
- 14.5. Market Trends
- 14.6. Key Market Participants - Intensity Mapping
- 14.7. Drivers and Restraints - Impact Analysis
- 14.8. Country Level Analysis & Forecast
- 14.8.1. Germany Pulmonary Fibrosis Treatment Market Analysis
- 14.8.1.1. Introduction
- 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 14.8.1.2.1. By Therapy Type
- 14.8.1.2.2. By Indication
- 14.8.1.2.3. By Distribution Channel
- 14.8.2. Italy Pulmonary Fibrosis Treatment Market Analysis
- 14.8.2.1. Introduction
- 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 14.8.2.2.1. By Therapy Type
- 14.8.2.2.2. By Indication
- 14.8.2.2.3. By Distribution Channel
- 14.8.3. France Pulmonary Fibrosis Treatment Market Analysis
- 14.8.3.1. Introduction
- 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 14.8.3.2.1. By Therapy Type
- 14.8.3.2.2. By Indication
- 14.8.3.2.3. By Distribution Channel
- 14.8.4. U.K. Pulmonary Fibrosis Treatment Market Analysis
- 14.8.4.1. Introduction
- 14.8.4.2. Market Analysis and Forecast by Market Taxonomy
- 14.8.4.2.1. By Therapy Type
- 14.8.4.2.2. By Indication
- 14.8.4.2.3. By Distribution Channel
- 14.8.5. Spain Pulmonary Fibrosis Treatment Market Analysis
- 14.8.5.1. Introduction
- 14.8.5.2. Market Analysis and Forecast by Market Taxonomy
- 14.8.5.2.1. By Therapy Type
- 14.8.5.2.2. By Indication
- 14.8.5.2.3. By Distribution Channel
- 14.8.6. Russia Pulmonary Fibrosis Treatment Market Analysis
- 14.8.6.1. Introduction
- 14.8.6.2. Market Analysis and Forecast by Market Taxonomy
- 14.8.6.2.1. By Therapy Type
- 14.8.6.2.2. By Indication
- 14.8.6.2.3. By Distribution Channel
- 14.8.7. BENELUX Pulmonary Fibrosis Treatment Market Analysis
- 14.8.7.1. Introduction
- 14.8.7.2. Market Analysis and Forecast by Market Taxonomy
- 14.8.7.2.1. By Therapy Type
- 14.8.7.2.2. By Indication
- 14.8.7.2.3. By Distribution Channel
15. East Asia Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033
- 15.1. Introduction
- 15.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
- 15.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
- 15.3.1. By Country
- 15.3.1.1. China
- 15.3.1.2. Japan
- 15.3.1.3. South Korea
- 15.3.2. By Therapy Type
- 15.3.3. By Indication
- 15.3.4. By Distribution Channel
- 15.4. Market Attractiveness Analysis
- 15.4.1. By Country
- 15.4.2. By Therapy Type
- 15.4.3. By Indication
- 15.4.4. By Distribution Channel
- 15.5. Market Trends
- 15.6. Key Market Participants - Intensity Mapping
- 15.7. Drivers and Restraints - Impact Analysis
- 15.8. Country Level Analysis & Forecast
- 15.8.1. China Pulmonary Fibrosis Treatment Market Analysis
- 15.8.1.1. Introduction
- 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.1.2.1. By Therapy Type
- 15.8.1.2.2. By Indication
- 15.8.1.2.3. By Distribution Channel
- 15.8.2. Japan Pulmonary Fibrosis Treatment Market Analysis
- 15.8.2.1. Introduction
- 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.2.2.1. By Therapy Type
- 15.8.2.2.2. By Indication
- 15.8.2.2.3. By Distribution Channel
- 15.8.3. South Korea Pulmonary Fibrosis Treatment Market Analysis
- 15.8.3.1. Introduction
- 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.3.2.1. By Therapy Type
- 15.8.3.2.2. By Indication
- 15.8.3.2.3. By Distribution Channel
16. South Asia Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033
- 16.1. Introduction
- 16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
- 16.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
- 16.3.1. By Country
- 16.3.1.1. India
- 16.3.1.2. Indonesia
- 16.3.1.3. Malaysia
- 16.3.1.4. Thailand
- 16.3.1.5. Rest of South Asia
- 16.3.2. By Therapy Type
- 16.3.3. By Indication
- 16.3.4. By Distribution Channel
- 16.4. Market Attractiveness Analysis
- 16.4.1. By Country
- 16.4.2. By Therapy Type
- 16.4.3. By Indication
- 16.4.4. By Distribution Channel
- 16.5. Market Trends
- 16.6. Key Market Participants - Intensity Mapping
- 16.7. Drivers and Restraints - Impact Analysis
- 16.8. Country Level Analysis & Forecast
- 16.8.1. India Pulmonary Fibrosis Treatment Market Analysis
- 16.8.1.1. Introduction
- 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.1.2.1. By Therapy Type
- 16.8.1.2.2. By Indication
- 16.8.1.2.3. By Distribution Channel
- 16.8.2. Indonesia Pulmonary Fibrosis Treatment Market Analysis
- 16.8.2.1. Introduction
- 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.2.2.1. By Therapy Type
- 16.8.2.2.2. By Indication
- 16.8.2.2.3. By Distribution Channel
- 16.8.3. Malaysia Pulmonary Fibrosis Treatment Market Analysis
- 16.8.3.1. Introduction
- 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.3.2.1. By Therapy Type
- 16.8.3.2.2. By Indication
- 16.8.3.2.3. By Distribution Channel
- 16.8.4. Thailand Pulmonary Fibrosis Treatment Market Analysis
- 16.8.4.1. Introduction
- 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.4.2.1. By Therapy Type
- 16.8.4.2.2. By Indication
- 16.8.4.2.3. By Distribution Channel
17. Oceania Pulmonary Fibrosis Treatment Market 2019-2023 and Forecast 2024-2033
- 17.1. Introduction
- 17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
- 17.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
- 17.3.1. By Country
- 17.3.1.1. Australia
- 17.3.1.2. New Zealand
- 17.3.2. By Therapy Type
- 17.3.3. By Indication
- 17.3.4. By Distribution Channel
- 17.4. Market Attractiveness Analysis
- 17.4.1. By Country
- 17.4.2. By Therapy Type
- 17.4.3. By Indication
- 17.4.4. By Distribution Channel
- 17.5. Key Trends
- 17.6. Key Market Participants - Intensity Mapping
- 17.7. Drivers and Restraints - Impact Analysis
- 17.8. Country Level Analysis & Forecast
- 17.8.1. Australia Pulmonary Fibrosis Treatment Market Analysis
- 17.8.1.1. Introduction
- 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 17.8.1.2.1. By Therapy Type
- 17.8.1.2.2. By Indication
- 17.8.1.2.3. By Distribution Channel
- 17.8.2. New Zealand Pulmonary Fibrosis Treatment Market Analysis
- 17.8.2.1. Introduction
- 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 17.8.2.2.1. By Therapy Type
- 17.8.2.2.2. By Indication
- 17.8.2.2.3. By Distribution Channel
18. Middle East and Africa (MEA) Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033
- 18.1. Introduction
- 18.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
- 18.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
- 18.3.1. By Country
- 18.3.1.1. Turkey
- 18.3.1.2. GCC Countries
- 18.3.1.3. South Africa
- 18.3.1.4. North Africa
- 18.3.1.5. Rest of MEA
- 18.3.2. By Therapy Type
- 18.3.3. By Indication
- 18.3.4. By Distribution Channel
- 18.4. Market Attractiveness Analysis
- 18.4.1. By Country
- 18.4.2. By Therapy Type
- 18.4.3. By Indication
- 18.4.4. By Distribution Channel
- 18.5. Market Trends
- 18.6. Key Market Participants - Intensity Mapping
- 18.7. Drivers and Restraints - Impact Analysis
- 18.8. Country Level Analysis & Forecast
- 18.8.1. Turkey Pulmonary Fibrosis Treatment Market Analysis
- 18.8.1.1. Introduction
- 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 18.8.1.2.1. By Therapy Type
- 18.8.1.2.2. By Indication
- 18.8.1.2.3. By Distribution Channel
- 18.8.2. GCC Countries Pulmonary Fibrosis Treatment Market Analysis
- 18.8.2.1. Introduction
- 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 18.8.2.2.1. By Therapy Type
- 18.8.2.2.2. By Indication
- 18.8.2.2.3. By Distribution Channel
- 18.8.3. South Africa Pulmonary Fibrosis Treatment Market Analysis
- 18.8.3.1. Introduction
- 18.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 18.8.3.2.1. By Therapy Type
- 18.8.3.2.2. By Indication
- 18.8.3.2.3. By Distribution Channel
- 18.8.4. North Africa Pulmonary Fibrosis Treatment Market Analysis
- 18.8.4.1. Introduction
- 18.8.4.2. Market Analysis and Forecast by Market Taxonomy
- 18.8.4.2.1. By Therapy Type
- 18.8.4.2.2. By Indication
- 18.8.4.2.3. By Distribution Channel
19. Market Structure Analysis
- 19.1. Market Analysis by Tier of Companies
- 19.2. Market Share Analysis of Top Players
- 19.3. Market Presence Analysis
20. Competition Analysis
- 20.1. Competition Dashboard
- 20.2. Competition Deep Dive
- 20.2.1. F. Hoffman - La Roche Ltd.
- 20.2.1.1. Overview
- 20.2.1.2. Service Portfolio
- 20.2.1.3. Key Financials
- 20.2.1.4. Sales Footprint
- 20.2.1.5. Strategy Overview
- 20.2.1.5.1. Marketing Strategy
- 20.2.1.5.2. Product Strategy
- 20.2.1.5.3. Channel Strategy
- 20.2.2. Boehringer Ingelheim
- 20.2.2.1. Overview
- 20.2.2.2. Service Portfolio
- 20.2.2.3. Key Financials
- 20.2.2.4. Sales Footprint
- 20.2.2.5. Strategy Overview
- 20.2.2.5.1. Marketing Strategy
- 20.2.2.5.2. Product Strategy
- 20.2.2.5.3. Channel Strategy
- 20.2.3. International GmbH
- 20.2.3.1. Overview
- 20.2.3.2. Service Portfolio
- 20.2.3.3. Key Financials
- 20.2.3.4. Sales Footprint
- 20.2.3.5. Strategy Overview
- 20.2.3.5.1. Marketing Strategy
- 20.2.3.5.2. Product Strategy
- 20.2.3.5.3. Channel Strategy
- 20.2.4. Cipla Ltd (Cipla)
- 20.2.4.1. Overview
- 20.2.4.2. Service Portfolio
- 20.2.4.3. Key Financials
- 20.2.4.4. Sales Footprint
- 20.2.4.5. Strategy Overview
- 20.2.4.5.1. Marketing Strategy
- 20.2.4.5.2. Product Strategy
- 20.2.4.5.3. Channel Strategy
- 20.2.5. Gilead Sciences, Inc.
- 20.2.5.1. Overview
- 20.2.5.2. Service Portfolio
- 20.2.5.3. Key Financials
- 20.2.5.4. Sales Footprint
- 20.2.5.5. Strategy Overview
- 20.2.5.5.1. Marketing Strategy
- 20.2.5.5.2. Product Strategy
- 20.2.5.5.3. Channel Strategy
- 20.2.6. Bristol-Myers Squibb Company
- 20.2.6.1. Overview
- 20.2.6.2. Service Portfolio
- 20.2.6.3. Key Financials
- 20.2.6.4. Sales Footprint
- 20.2.6.5. Strategy Overview
- 20.2.6.5.1. Marketing Strategy
- 20.2.6.5.2. Product Strategy
- 20.2.6.5.3. Channel Strategy
- 20.2.7. FibroGen Inc.,
- 20.2.7.1. Overview
- 20.2.7.2. Service Portfolio
- 20.2.7.3. Key Financials
- 20.2.7.4. Sales Footprint
- 20.2.7.5. Strategy Overview
- 20.2.7.5.1. Marketing Strategy
- 20.2.7.5.2. Product Strategy
- 20.2.7.5.3. Channel Strategy
- 20.2.8. Galecto, Inc.
- 20.2.8.1. Overview
- 20.2.8.2. Service Portfolio
- 20.2.8.3. Key Financials
- 20.2.8.4. Sales Footprint
- 20.2.8.5. Strategy Overview
- 20.2.8.5.1. Marketing Strategy
- 20.2.8.5.2. Product Strategy
- 20.2.8.5.3. Channel Strategy
21. Assumptions and Acronyms Used
22. Research Methodology
